N4 PHARMA PLC — Major Shareholding Notification 2017

Jun 6, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

For filings with the FCA include the annex For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Aisling Capital Management LP Aisling Capital IV LP
4. Full name of shareholder(s) (if different from 3.):iv		Aisling Capital IV LP
5. Date of the transaction and date on which the threshold is crossed or reached: v		05/19/2017
6. Date on which issuer notified:		05/26/2017
7. Threshold(s) that is/are crossed or reached: vi, vii		Upward crossing of 3% threshold

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares
Direct		Direct xi		Indirect xii	Direct
Ordinary ISIN GB00B06GSH43							1,474,688       2,074,080
ADS ISIN US9250501064
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii
Total (A+B+C)
Number of voting rights
3,548,768

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Aisling Capital IV LP (which holds 3,548,768 shares in the Company (3.38%)) is managed by Aisling Capital Management LP.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
** 13. Additional information:**
14. Contact name:	Robert Wenzel
15. Contact telephone number:	212-651-6374

Note: Annex should only be submitted to the FCA not the issuer Annex: Notification of major interests in share (xxii)
A: Identity of the persons or legal entity subject to the notification obligation
Full name (including legal form of legal entities)	Aisling Capital IV LP
Contact address (registered office for legal entities)	888 7th Avenue, 12th floor New York, NY 10106
Phone number & email	212-651-6380 / rwenzel@aislingcapital.com
Other useful information (at least legal representative for legal persons)
B: Identity of the notifier, if applicable
Full name
Contact address
Phone number & email
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)
C: Additional information
For notes on how to complete form TR-1 please see the FCA website.

---

*This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via Globenewswire*